USPIO-enhanced magnetic resonance imaging of the knee in asymptomatic volunteers by Reiner, C S et al.
Eur Radiol (2009) 19: 1715–1722
DOI 10.1007/s00330-009-1343-4 CONTRAST MEDIA
C. S. Reiner
A. M. Lutz
F. Tschirch
J. M. Froehlich
S. Gaillard
B. Marincek
D. Weishaupt
Received: 24 August 2008
Accepted: 11 January 2009
Published online: 28 March 2009
# European Society of Radiology 2009
USPIO-enhanced magnetic resonance imaging
of the knee in asymptomatic volunteers
Abstract The aim of this study was to
compare signal characteristics of the
synovium in knees of asymptomatic
volunteers before and after intrave-
nous administration of ultrasmall
superparamagnetic iron oxide
particles (USPIO). Ten knees of 10
asymptomatic volunteers were exam-
ined before and 36 h after intravenous
administration of USPIO on a 1.5-T
MR system using T1-weighted spin-
echo, T2-weighted fast spin-echo,
T2*-weighted gradient-echo (GRE),
and short inversion time inversion-
recovery sequences. In addition,
synovial perfusion was measured
using Gd-enhanced GRE imaging
during the first imaging session.
Images were analyzed qualitatively
for any visual changes before and after
USPIO administration. Signal-to-
noise ratios (SNR) of the synovium
were determined on unenhanced and
USPIO-enhanced sequences. All MR
images were reviewed for presence of
any degenerative changes. Qualitative
image analysis revealed no visually
detectable changes of any knee joint
before and after USPIO administra-
tion. The SNR values of the synovium
on T1w, T2w, and T2*w images
before and after USPIO administration
showed no significant difference (T1,
P=0.86; T2, P=0.95; T2*, P=0.86).
None of the volunteers showed any
relevant degenerative changes of the
knee and synovial perfusion was
within normal limits. In knees of
asymptomatic volunteers without any
relevant degenerative changes and
normal synovial perfusion neither
visual changes nor changes of SNR
values of the synovium can be
depicted after USPIO administration.
This means that USPIO-enhanced
MRI may be used for assessment of
knee disorders with increased
macrophage activity.
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particles . Magnetic resonance
imaging . Knee . Macrophages
Introduction
The potentials of cell-specific MR imaging (MRI) using
superparamagnetic nanoparticles for imaging of musculo-
skeletal disorders have been recently recognized. Findings
of several in vitro and in vivo studies have shown that
superparamagnetic iron oxide particles (SPIO) and ultra-
small superparamagnetic iron oxide particles (USPIO) are
phagocytosed by macrophages [1]. Therefore, large
collections of macrophages in inflammatory tissues and
the resulting signal changes may be detected by MRI on
delayed T2-weighted or T2*-weighted sequences [2–7] in
(U)SPIO-enhanced imaging.
Since macrophages play an important role in the
pathogenesis of rheumatoid arthritis (RA) [8, 9], the
technique is of particular interest in order to improve
the diagnostic performance of imaging in this inflam-
matory joint disease. As the amount of macrophages
residing within the synovium in RA is influenced by
the grade of neoangiogenesis and resulting synovial
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hyperperfusion [10], the extent of signal changes on
iron oxide-enhanced MR images may depend on the
grade of synovial hyperperfusion. Several studies in
animal models of antigen-induced arthritis have shown
that both SPIO and USPIO allow specific detection of
macrophage infiltration of the synovial membrane [2,
6, 11, 12]. These results have led to the conclusion that iron
oxide nanoparticles-enhanced MRI may also be useful for
human applications in particular for the assessment of early
stages of arthritis which are currently not sufficiently
detectable by the current imaging modalities or for
monitoring of disease activity [6, 13, 14].
Despite the promising animal data, to the best of our
knowledge, the USPIO-enhanced MRI for imaging of
inflammatory joint disease has not been used in humans.
However, before a new imaging technique is used in
diseased patients it may be of interest to investigate
asymptomatic volunteers in order to define normal findings
and to exclude nonspecific signal effects. Therefore, the
purpose of our study was to assess the signal characteristics
of the synovium in knees of asymptomatic volunteers
before and after intravenous administration of USPIO.
Materials and methods
Volunteers
Eleven volunteers (six females, five males; mean age,
35.7 years; range, 22–50 years) who met the inclusion
criteria and consented to participate were included in the
study. The study was approved by the Institutional Review
Board, was notified to the national regulatory authorities,
and written informed consent was obtained from each
volunteer. Each participant was only included if there was
no history of inflammatory joint disease, no history of knee
surgery, no history of a relevant knee trauma nor knee pain
in the last 6 months. The exclusion criteria were a general
contraindication to MRI, a known previous reaction to MR
contrast agents, drugs (including dextran) or food, preg-
nancy or hemochromatosis.
Study design
The volunteers underwent two imaging sessions. In each
volunteer one knee was examined (the right knee in eight
volunteers, the left knee in three volunteers). The first MRI
session was performed as the baseline study before admin-
istration of USPIO (unenhanced imaging) and for acquisition
of the synovial perfusion. In order to detect any kind of
synovial hyperperfusion which could influence the character-
istics of USPIO-enhanced imaging of the knee in otherwise
healthy volunteers, synovial perfusion was measured. To
acquire perfusion images an extracellular gadolinium (Gd)-
based contrast agent was administered intravenously as a
bolus injection during the first MRI session. After finishing
the first imaging session, USPIO was administered intrave-
nously as a slow drip infusion (see below). The second MRI
session (enhanced imaging) was performed 36 h after USPIO
administration. During this second imaging session no
additional contrast agent was administered.
MR imaging
MR imaging of the knee of each asymptomatic volunteer
was performed on a 1.5-T MR system (Signa EchoSpeed
EXCITE® HD or HDx, GE Healthcare, Waukesha,
Wisconsin, USA) using a dedicated phased-array knee
coil. We chose to perform imaging on a 1.5-T system, since
this represents the clinically most widely available field
strength. The same MR machine and coil were used for
both imaging sessions. The knee was imaged in the exact
same position during both imaging sessions.
The imaging protocol for the first and the second
imaging session included T1-weighted (T1w) spin-echo
(SE) sequences, T2-weighted (T2w) fast SE (FSE)
sequences, T2*-weighted (T2*w) gradient-echo (GRE)
sequences, and short inversion time inversion-recovery
(STIR) sequences and is displayed in Table 1. MR imaging
was performed in the transverse and sagittal plane for the
T1w, T2w, and T2*w sequences, and in the coronal plane
for the STIR sequences.
At the end of the first imaging session a series of eleven
multiphase fast GRE (FGRE) image sets (TR/TE,
100/14 msec; FOV, 160×160 mm; matrix, 256×192;
number of signals acquired, 1) was obtained in transversal
plane, with each image set consisting of four slices of
4-mm thickness at the level of the femoral condyles.
After acquisition of the first image set Gd-DOTA
(Dotarem®, Guerbet, Roissy, France) was injected into a
cubital vein while the volunteer remained in the same
position and the remaining ten image sets were obtained
with an update rate of one image set every 30 s.
Contrast agent
Tomeasure synovial perfusion 0.1mmolGd-DOTA/kg body
weight (Dotarem,Guerbet, Roissy, France) was administered
intravenously as bolus injection with a power injector
(Spectris; Medrad, Indianola, Pa) at a flow rate of 3 ml/s
followed by a 20-ml saline flush during the first imaging
session for the acquisition of the perfusion sequences.
The USPIO contrast agent used in this study was
ferumoxtran-10 (Sinerem®, Guerbet, Roissy, France) with
an overall mean particle diameter of 20–30 nm. The
contrast agent (2.6 mg iron/kg body weight corresponding
to 45 μmol/kg body weight, diluted in 100 ml of 0.9%
saline solution) was administered intravenously as a slow
drip infusion through a 0.2-μm Sterifix® infusion filter set
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at a flow rate of 3 ml/min directly after the first imaging
session was completed. The total infusion time was
approximately 30 min. Potential adverse effects during
contrast administration were noted.
Image analysis
For qualitative and quantitative image analysis all MR
images were transferred to a dedicated, commercially
available workstation (Advantage Workstation 4.2; GE
Medical Systems, Buc, France). Qualitative image analysis
was performed in a consensus reading by two radiologists
in a blinded fashion. Both readers were blinded to the
volunteer’s names, age, sex, and any clinical information
other than the inclusion criteria. Quantitative analysis with
regard to the degree of synovial perfusion as well as signal
changes following ferumoxtran-10 administration was
performed separately by one radiologist (see below).
Qualitative analysis
Assessment of joint abnormalities MR studies were
reviewed for signs of osteoarthritis such as cartilage
defects and osteophytes in the medial and lateral tibio-
femoral and patellofemoral joint compartments, tibial and
femoral subchondral cysts, joint effusion, and for
abnormalities of the medial and lateral menisci [15–18].
Meniscal abnormalities included intrasubstance degen-
eration and meniscal tears which were graded following
the MR imaging criteria described by Crues et al. [19].
Assessment of visual changes following ferumoxtran-10
administration The readers evaluated pairwise unenhanced
images of the first imaging session and enhanced images
of the second imaging session with regard to the presence
or absence of visual changes in the signal characteristics of
the synovium and the synovial fluid between unenhanced
and enhanced T1w SE, T2w FSE, and T2*w GRE images.
Quantitative analysis
Synovial perfusion The multiphase FGRE images were
analyzed using the “Functool” software package (GE
Medical Systems, Buc, France) installed on the work-
station. On multiphase FGRE images defined round or
elliptic regions of interest (ROI) between 5 and 10 mm2
were placed, one within the synovium and one within the
muscle tissue of each knee joint. Because the synovium and
the joint capsule could not be distinguished as separate
anatomic structures they were considered a single structure
for signal intensity (SI) measurements. The relative
enhancement of the synovium (REs) and the muscle tissue
(REm) at t seconds was calculated according to the formula
REt ¼ SI t  SI0ð Þ

SI0  100% . SI0 and SIt are defined as
the SI before and t seconds after Gd contrast injection.
Assessment of signal changes following ferumoxtran-10
administration On unenhanced and enhanced T1w SE,
T2w FSE, and T2*w GRE images SI measurements were
obtained by means of ROIs with a diameter of 1–5 mm2.
Three ROIs were placed within comparable locations
within the synovium. The mean values of the three ROIs
were calculated for further analysis. In addition, the
background noise was measured within three ROIs placed
in a region of the image outside the knee. Signal-to-noise
ratios (SNR) were calculated by dividing the mean of the
measured SI of the synovium by the standard deviation of
the background noise. The relative SNR changes between
pre- and postcontrast T1w, T2w, and T2*w images were
quantified using the following formula: SNRchange ¼
SNRpostcontrast  SNRprecontrast
 
SNRprecontrast
  100 .
Statistical analysis
The results of RE measurements of synovium and muscle
tissue on perfusion images and the SNR values of the
Table 1 MR imaging parameters for the first and second imaging session
T1w SE T2w FSE T2*w GRE STIR
Repetition time/echo time (ms) 325/15.7 3,300/85 500/15 3,975/34
Inversion time (ms) – – – 150
Echo train length – 16 – 16
Field of view (mm) 160×160 160×160 160×160 160×160
Matrix 256×224 256×224 256×224 256×192
Signals acquired 2 2 2 2
Flip angle (degrees) – – 25 –
Slice thickness/gap (mm) 4/0.4 4/0.4 4/0.4 3/1
Voxel size (mm) 0.63×0.71×4 0.63×0.71×4 0.63×0.71×4 0.63×0.83×3
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synovium on pre- and post-USPIO images are given as
mean ± standard deviation (SD). In addition, the difference
between RE of synovium and muscle tissue at each time-
point t was calculated in percent. The Wilcoxon signed-
rank test was used to compare the RE of the synovium and
muscle tissue at each time-point t on perfusion images and
to compare the SNR values of the synovium before and
after administration of USPIO. A P value of less than 0.05
was considered to indicate a statistically significant
difference.
The statistical analysis was performed using the SPSS
Software (SPSS 12.0.1 Inc., Chicago, IL, USA).
Results
In 1 of 11 (9%) volunteers moderate adverse effects
occurred 2 min after the start of the USPIO infusion,
including flush, perioral paresthesia, nausea, and near
collapse. The infusion was stopped immediately and no
enhanced images were obtained impeding further evalua-
tion of this volunteer. Thus, the entire protocol with both
imaging sessions could be completed in ten asymptomatic
volunteers and a total of ten knees were available for
analysis. In nine out of the remaining ten (90%) volunteers,
no subjective or objective adverse effects during adminis-
tration of the contrast agents were reported. In one single
volunteer (10%), mild adverse effects (pruritus and
urticaria) occurred following USPIO administration.
Nevertheless, the second imaging session could be
completed.
Qualitative analysis
Assessment of joint abnormalities
Significant signs of osteoarthritis were absent in all
evaluated knees. The evaluation for signs of osteoarthritis
revealed minor cartilage lesions in six knees (60%).
Osteophytes and subchondral cysts were seen in none of
the knee joints. In one out of ten knee joints (10%) a small
joint effusion was present in the suprapatellar recess.
Meniscal intrasubstance degeneration was found in four
(40%) knees (medial menisci) and a nondisplaced tear was
found in two (20%) knees (one lateral and one medial
meniscus). In the knee with the nondisplaced tear of the
lateral meniscus the medial meniscus showed a displaced
tear in the posterior horn.
Assessment of visual changes following
ferumoxtran-10 administration
Qualitative image analysis revealed no visual changes in
the signal characteristics of the synovium and the synovial
fluid of any of the knees between pre- and postcontrast
T1w, T2w, and T2*w images (Fig. 1). The subjective
findings of the qualitative analysis of signal characteristics
were in accordance with the results of the quantitative
analysis of pre- and postcontrast images.
Quantitative analysis
Assessment of synovial perfusion
The RE of synovial and muscular tissue was calculated for
each time-point t, showing a mean maximum value of 25±
12% (range, 7–44%) for synovial tissue and a mean
maximum value of 40±10% (range, 26–59%) for muscular
tissue. The synovium enhanced to a lesser degree than
muscular tissue with an RE that was consistently lower by
17±14% (P<0.001). The course of the mean RE of the
synovial and the muscular tissue of ten volunteers’ knees
following Gd-DOTA is shown in Fig. 2. Synovial and
muscular tissue did not show any high early enhancement,
followed by a late static enhancement, as one would expect
in inflamed knee joints [14, 20]. In conclusion these results
did not reveal any evidence for synovial hyperperfusion in
the evaluated knee joints.
Assessment of signal changes following
ferumoxtran-10 administration
The SNR values of the synovium as measured in each
volunteer on unenhanced and enhanced T1 w, T2w, and
T2*w images are displayed in Table 2. When the SNR
values before and 36 h after USPIO administration were
compared, no statistically significant differences were
detected on T1w, T2w, and T2*w images (P=0.96, P=
0.96, P=0.80). The mean relative SNR changes between
unenhanced and enhanced images were 3.6%±12.5 on T1w
sequences, 2.5%±13.5 on T2w sequences, and 0.7%±16.9
on T2*w sequences.
Discussion
Increased perfusion of the synovial tissue due to
neoangiogenesis as well as inflammatory cellular infil-
tration in affected joints are important characteristics of
rheumatoid arthritis (RA) [9, 10, 14]. Among the
involved inflammatory cells, macrophages play a pivotal
role in the pathogenesis and continuance of RA. The
number of macrophages accumulating in the synovial
tissue of affected joints is known to positively correlate
to grade of joint destruction, pain, and prognosis in RA
[8, 21]. An important novel class of disease-modifying
drugs, anti-TNF-α agents, has been shown to mainly
target macrophages and their cytokines [22]. More
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recent therapy approaches, therefore, target neoangio-
genesis to suppress inflammation and prevent irrevers-
ible joint destruction [10, 22–25]. In order to balance
risk and benefit as well as costs of this therapy strategy,
sensitive and specific diagnostic imaging methods are
required for the detection of early inflammatory changes
in active RA and for close therapy monitoring. For this
purpose, imaging approaches capable of assessing
synovial macrophage content and synovial perfusion
may be beneficial in the therapy monitoring. The
Fig. 2 Mean relative enhance-
ment (RE) of the synovial and
the muscular tissue in each of
the 11 image sets of the multi-
phase FGRE sequences acquired
before (image number 1) and
after (image numbers 2–11) Gd-
DOTA administration. The
curves illustrate the course of
the mean RE of the synovium
and the muscular tissue as mea-
sured in ten volunteers’ knees,
which show only moderate early
relative enhancement of the sy-
novial and muscular tissue
Fig. 1 Sagittal images of the knee of a 47-year-old asymptomatic
volunteer before (a–c) and 36 h after (d, f) USPIO administration
obtained in the following sequences: a and d, T1w SE (TR/TE,
325/15.7 ms); b and e, T2w FSE (TR/TE, 3,300/85 ms); c and f,
T2*w GRE (TR/TE, 500/15 ms). No visual changes in the signal
characteristics of the synovium and the synovial fluid between pre-
and postcontrast T1w, T2w, and T2*w images were detected. The
SNR values of the synovium measured on precontrast images were
18.6 on T1w (a), 17.1 on T2w (b), and 9.5 on T2*w (c) sequences.
On postcontrast images the SNR values of the synovium were 17.0
on T1w (d), 16.2 on T2w (e), and 8.0 on T2*w (f) sequences
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feasibility of macrophage-specific imaging using macro-
phage tagging by SPIO/USPIO has been shown in
numerous animal studies [6, 11–13, 26, 27]. Iron oxide
nanoparticles such as SPIO and USPIO can cause
pronounced MR signal effects even after application of
doses in the range of micromoles/kg body weight that
are detectable using standard 1.5-T scanner systems [4,
13, 28]. Since SPIO/USPIO nanoparticles are specifi-
cally taken up by cells of the mononuclear phagocytic
system, SPIO/USPIO-enhanced MR imaging is a very
promising approach for the detection of macrophages in
inflammatory joint disease. Accordingly, promising
results were shown using SPIO/USPIO-enhanced MR
imaging for macrophage detection in animal models of
antigen-induced arthritis [6, 11, 12, 27].
To date, however, it is not clear whether the results of
animal studies can be readily translated into humans.
However, before this novel imaging strategy can be tested in
patients it is helpful to investigate asymptomatic volunteers
in order to define normal findings, exclude nonspecific
USPIO uptake, and optimize the imaging setup.
In our study we were able to confirm the findings of
USPIO-enhanced MRI of nonarthritic knees in animal
models. Neither qualitative nor quantitative changes in
signal characteristics of the synovial tissue were observed in
any of the ten knees of healthy volunteers. However, it has to
be underlined that there was no higher grade knee degen-
eration. No synovial hyperperfusion was detected, which
was also in accordance with MRI studies analyzing synovial
perfusion in normal and arthritic knees [13, 14, 29].
USPIO-enhanced MRI can combine two approaches in
imaging of arthritic joints: first, USPIO administration
provides the possibility to quantify synovial macrophages,
which correlate with disease severity; second, synovial
perfusion could be assessed immediately after USPIO
administration in arthritic joints. Several studies demon-
strated that dynamic Gd-enhanced MRI of arthritic joints
can reveal information regarding synovial perfusion and
disease activity [14, 20, 29, 30] and can depict effects of
treatment by showing a decrease in the enhancement rate in
the arthritic knee [31, 32]. Lutz et al. [13] combined these
two approaches in a rabbit model of antigen-induced
arthritis using USPIO-enhanced MRI demonstrating that
early synovial hyperperfusion (within the first 56 s after
low dose bolus administration of ferumoxtran-10) and
synovial macrophages can be detected in arthritic knees on
USPIO-enhanced MRI. No early synovial hyperperfusion
or synovial macrophages were detectable in nonarthritic
control knees. Moreover, neovascularisation reflected by
increased vessel density within the synovium of arthritic
knees was detected following USPIO administration. To
date, this approach with bolus ferumoxtran-10 administra-
tion is not transferable to humans, because ferumoxtran-10
can only be administered as slow drip infusion. Therefore,
we used Gd-DOTA in our study to assess synovial
perfusion. When bolus-injectable USPIO agents become
available, both purposes may be accomplished with one
single contrast agent.
The major limitation of our study is that we performed
USPIO-enhanced MRI of the knee only in healthy
volunteers. However, the aim of our study was to define
normal signal characteristics and exclude nonspecific syno-
vial signal effects, before implementing this new imaging
technique in diseased patients with rheumatoid arthritis.
Table 2 Results of quantitative analysis of signal changes in the individual volunteers
Volunteer SNR prea SNR postb Relative SNR changes (%)
T1w T2w T2*w T1w T2w T2*w T1w T2w T2*w
1 51.1 10.7 13.5 47.1 13.7 17.3 −8.0 28.4 28.0
2 23.9 10.7 11.6 25.0 10.4 8.7 4.8 −2.4 −25.0
3 10.7 6.6 8.0 13.6 8.0 9.2 27.2 20.2 14.7
4 26.5 23.1 8.5 24.6 19.6 8.9 −7.1 −15.1 5.8
5 22.3 12.5 12.8 22.0 12.6 12.8 −1.4 0.9 −0.2
6 11.1 8.8 11.0 11.4 9.1 13.4 2.5 3.1 21.3
7 18.6 17.1 9.5 17.0 16.2 8.0 −8.9 −5.0 −14.9
8 12.6 8.6 11.1 14.6 8.1 10.3 16.0 −5.8 −6.6
9 23.0 16.0 14.9 21.6 17.5 12.9 −6.1 9.8 −13.2
10 19.4 14.1 21.7 22.7 12.7 21.1 16.6 −9.5 −2.9
Meanc 21.9 12.8 12.2 22.0 12.8 12.3 3.6 2.5 0.7
SD 11.7 4.9 4.0 10.0 4.0 4.2 12.5 13.5 16.9
SD standard deviation, SNR signal-to-noise ratio
aSNR of the synovium measured on unenhanced images
bSNR of the synovium measured on USPIO-enhanced images
cMean values of SNR and relative SNR changes
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Since we only analyzed a 36-h time delay between
administration and imaging, our results are limited to this
time frame, a 24- to 36-h time delay being the preferred one
for most of the envisaged clinical indications.
Conclusion
Our results have shown that in knees of asymptomatic
volunteers with absence of relevant degenerative changes
and normal synovial perfusion characteristics neither visual
changes nor changes with regard to the SNR of the
synovium can be depicted after USPIO administration.
USPIO-enhanced MRI is not hampered by nonspecific
signal changes in normal control knees and may be used for
assessment of knee disorders with increased macrophage
activity. These results lay the foundations for future studies
in patients with RA.
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